A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.
Mortality Signal Emerges 2 Years After Valve-in-Valve TAVR for Failed SAVR
For patients with failed bioprosthetic surgical valves, the choice of valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) carried upfront advantages, but was ultimately associated with
May 23, 2024